GFAP and Alzheimer disease: Additionally, we further confirm the lack of efficacy of STZ in C57BL/6 mice at the molecular level by analyzing reactive astrogliosis through GFAP immunohistochemistry, a reliable marker of neurodegeneration in both STZ-icv models and AD patients (Fig. 3).